aTyr Pharma (NASDAQ:LIFE) Shares Cross Above Two Hundred Day Moving Average of $0.00

aTyr Pharma, Inc. (NASDAQ:LIFE) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $4.83. aTyr Pharma shares last traded at $4.69, with a volume of 245,105 shares.

A number of equities analysts have issued reports on LIFE shares. Roth Capital lifted their price objective on shares of aTyr Pharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, March 16th. Laidlaw started coverage on shares of aTyr Pharma in a research note on Monday, May 10th. They set a “buy” rating and a $18.00 price target for the company. Zacks Investment Research upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Friday, March 26th. Oppenheimer lifted their price objective on shares of aTyr Pharma from $12.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, March 30th. Finally, Jonestrading assumed coverage on shares of aTyr Pharma in a research note on Tuesday, May 18th. They issued a “buy” rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. aTyr Pharma currently has an average rating of “Buy” and a consensus target price of $14.08.

The firm’s 50-day moving average price is $4.15. The stock has a market cap of $76.63 million, a PE ratio of -2.03 and a beta of 2.04.

aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Thursday, May 13th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.17). aTyr Pharma had a negative return on equity of 67.48% and a negative net margin of 155.18%. Equities research analysts anticipate that aTyr Pharma, Inc. will post -1.74 earnings per share for the current fiscal year.

In other aTyr Pharma news, CEO Sanjay Shukla bought 10,000 shares of aTyr Pharma stock in a transaction on Tuesday, May 18th. The stock was acquired at an average price of $4.01 per share, with a total value of $40,100.00. Following the acquisition, the chief executive officer now owns 18,298 shares in the company, valued at $73,374.98. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Schimmel bought 50,000 shares of aTyr Pharma stock in a transaction on Tuesday, May 18th. The stock was acquired at an average cost of $3.98 per share, with a total value of $199,000.00. Following the acquisition, the director now owns 2,890 shares in the company, valued at approximately $11,502.20. The disclosure for this purchase can be found here. 5.14% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of LIFE. Alyeska Investment Group L.P. grew its holdings in aTyr Pharma by 16.7% during the first quarter. Alyeska Investment Group L.P. now owns 983,594 shares of the biotechnology company’s stock valued at $4,377,000 after purchasing an additional 141,040 shares during the period. Ikarian Capital LLC purchased a new position in shares of aTyr Pharma in the fourth quarter valued at about $1,552,000. BlackRock Inc. lifted its position in shares of aTyr Pharma by 528.3% in the first quarter. BlackRock Inc. now owns 253,389 shares of the biotechnology company’s stock valued at $1,127,000 after acquiring an additional 213,058 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of aTyr Pharma by 23.7% in the first quarter. Acadian Asset Management LLC now owns 102,697 shares of the biotechnology company’s stock valued at $457,000 after acquiring an additional 19,645 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in aTyr Pharma by 236.6% during the first quarter. Dimensional Fund Advisors LP now owns 64,400 shares of the biotechnology company’s stock valued at $287,000 after buying an additional 45,270 shares during the last quarter. 36.89% of the stock is owned by institutional investors.

aTyr Pharma Company Profile (NASDAQ:LIFE)

aTyr Pharma, Inc, a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19.

Featured Story: Why are analyst ratings important in trading stocks?

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.